[HTML][HTML] SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: a practical approach for routine clinical practice
A Giaccari, R Pontremoli, PP Filardi - International journal of cardiology, 2022 - Elsevier
Abstract Sodium-glucose cotransporter-2 inhibitors (SGLT-2i), initially studied and approved
for the treatment of diabetes, are now becoming a promising class of agents to treat heart …
for the treatment of diabetes, are now becoming a promising class of agents to treat heart …
SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: A practical approach for routine clinical practice
A Giaccari, R Pontremoli… - International journal of …, 2022 - pubmed.ncbi.nlm.nih.gov
Sodium-glucose cotransporter-2 inhibitors (SGLT-2i), initially studied and approved for the
treatment of diabetes, are now becoming a promising class of agents to treat heart failure …
treatment of diabetes, are now becoming a promising class of agents to treat heart failure …
SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: A practical approach for routine clinical practice
A Giaccari, R Pontremoli, P Perrone Filardi - INTERNATIONAL …, 2022 - iris.unina.it
Sodium-glucose cotransporter-2 inhibitors (SGLT-2i), initially studied and approved for the
treatment of diabetes, are now becoming a promising class of agents to treat heart failure …
treatment of diabetes, are now becoming a promising class of agents to treat heart failure …
SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: A practical approach for routine clinical practice.
A Giaccari, R Pontremoli - International Journal of Cardiology, 2022 - europepmc.org
Sodium-glucose cotransporter-2 inhibitors (SGLT-2i), initially studied and approved for the
treatment of diabetes, are now becoming a promising class of agents to treat heart failure …
treatment of diabetes, are now becoming a promising class of agents to treat heart failure …
[HTML][HTML] SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: A practical approach for routine clinical practice
A Giaccari, R Pontremoli… - International …, 2022 - internationaljournalofcardiology.com
Abstract Sodium-glucose cotransporter-2 inhibitors (SGLT-2i), initially studied and approved
for the treatment of diabetes, are now becoming a promising class of agents to treat heart …
for the treatment of diabetes, are now becoming a promising class of agents to treat heart …
SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: A practical approach for routine clinical practice
A Giaccari, R Pontremoli… - INTERNATIONAL …, 2022 - publicatt.unicatt.it
Abstract Sodium-glucose cotransporter-2 inhibitors (SGLT-2i), initially studied and approved
for the treatment of diabetes, are now becoming a promising class of agents to treat heart …
for the treatment of diabetes, are now becoming a promising class of agents to treat heart …
[PDF][PDF] SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: A practical approach for routine clinical practice
A Giaccari, R Pontremoli, PP Filardi - International Journal of …, 2022 - publicatt.unicatt.it
ABSTRACT Sodium-glucose cotransporter-2 inhibitors (SGLT-2i), initially studied and
approved for the treatment of diabetes, are now becoming a promising class of agents to …
approved for the treatment of diabetes, are now becoming a promising class of agents to …